IPO Comments on USPTO Supplemental Guidance Related to Design Patent Applications for Computer-Generated Interfaces and Icons
IPO Comments on USPTO Supplemental Guidance Related to Design Patent [...]
Resolution on Legislative Amendment to Anti-Cybersquatting Consumer Protection Act
RESOLVED, that IPO urges Congress to resolve the dispute among [...]
Resolution on Patent Subject Matter Eligibility
RESOLVED, that patent subject matter eligibility under 35 U.S.C. § 101 should [...]
IPO’s Request to the National Data Administration for an Extension of Time re: Comments on the “Guidelines for Data Property Rights Registration (Trial)”
IPO’s Request to the National Data Administration for an Extension [...]
Debunking Biopharmaceutical Patent Myths: An Evidence-Based Analysis
Debunking Biopharmaceutical Patent Myths: An Evidence-Based Analysis
IPO Comments to CNIPA on Draft Amendments to the Measures for the Administration of Patent Priority Examination
IPO Comments to CNIPA on Draft Amendments to the Measures [...]
You Can’t (Always) Claim What You Didn’t Describe: U.S. and European Perspectives on Chemical Patents
You Can’t (Always) Claim What You Didn’t Describe: U.S. and [...]
IPO Amicus Brief in Hikma Pharmaceuticals USA Inc., v. Amarin Pharma, Inc., 24-889
IPO Amicus Brief in Hikma Pharmaceuticals USA Inc., v. Amarin [...]
IPO Comments on Draft Agreement on Cross-Border Aspects of Client-Patent-Attorney Privilege
IPO Comments on Draft Agreement on Cross-Border Aspects of Client-Patent-Attorney [...]
IPO Post-Hearing Statement to Special 301 Subcommittee
IPO Post-Hearing Statement to Special 301 SubcommitteeReadability analysis: